Abstract
In the current coronavirus 2019 (COVID-19) pandemic, tocilizumab has gained widespread attention as a therapeutic option for the treatment of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection [1,2]. Tocilizumab is an interleukin-6 receptor (IL-6R) antagonist previously used for various rheumatological diseases, and now applied to treat cytokine release syndrome in COVID-19. IL-6R antagonists, however, may lead to higher susceptibility for opportunistic infections and increase the risk for pneumonia, urinary tract infections and cellulitis [3].
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
